sumv-1 Antibody
Description
What is SUMO-1 Antibody?
SUMO-1 antibodies are immunoreagents designed to detect SUMO-1 or SUMO-1-conjugated proteins. SUMOylation involves the covalent attachment of SUMO proteins to lysine residues on target proteins, modulating their localization, stability, or interactions . Antibodies targeting SUMO-1 are used across diverse applications, including Western blotting (WB), immunofluorescence (IF), and immunoprecipitation (IP) .
Validation and Performance
Recent studies highlight variability in SUMO-1 antibody performance across experimental formats:
Table 1: Sensitivity and Specificity of Select SUMO-1 Monoclonal Antibodies
| Antibody Clone | Host | Sensitivity (Dot Blot) | Specificity | Applications |
|---|---|---|---|---|
| Y299 | Rabbit | High (detects ≤10 ng) | SUMO-1 (pro/mature) | WB, IF, IP |
| 4D12 | Mouse | Low (negligible signal) | SUMO-1 (pro/mature) | WB |
| 8A2 | Rabbit | Moderate | SUMO-1 (mature) | IP, IF |
| 12F3 | Rabbit | High | SUMO-1 (pro/mature) | WB, IF |
Data derived from systematic testing of 24 SUMO MAbs using recombinant SUMO proteins .
Key Findings:
-
Y299 demonstrated the highest sensitivity, detecting rSUMO-1 at concentrations as low as 10 ng .
-
8A2 and 12F3 showed no cross-reactivity with SUMO-2/3/4, making them ideal for studies requiring isoform specificity .
-
ProSUMO-1 detection varies; antibodies like Y299 bind both pro and mature forms, while others (e.g., 8A2) favor the mature isoform .
Research Applications and Findings
SUMO-1 antibodies have been pivotal in:
-
Stress Response Studies: Elevated SUMOylation is observed under oxidative or thermal stress, detectable via WB/IF .
-
Cancer Research: Dysregulated SUMO-1 conjugation is linked to tumor progression; antibodies aid in profiling SUMOylated oncoproteins .
-
Neurological Disorders: Aberrant SUMO-1 modification is implicated in Parkinson’s and Alzheimer’s diseases .
Key Mechanistic Insights:
-
SUMO-1 antibodies enabled the discovery that SUMOylation stabilizes proteins like RanGAP1 at nuclear pore complexes, critical for nucleocytoplasmic transport .
-
In autoimmune contexts, SUMO-1 antibodies help identify autoantigens modified during disease progression .
Challenges and Considerations
-
Batch Variability: Commercial antibodies may exhibit lot-to-lot inconsistency, necessitating validation for each study .
-
Context-Dependent Performance: Antibodies like Y299 perform optimally in WB but may lack sensitivity in IP .
-
Polyclonal vs. Monoclonal: Polyclonal antibodies (e.g., ab5316) offer broad epitope recognition, while monoclonals (e.g., 8A2) provide reproducibility .
Future Directions
Advancements in SUMO-1 antibody development focus on:
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
Assumption: The query refers to "SUMO-1 Antibody" (Small Ubiquitin-like Modifier 1), a critical tool for studying post-translational protein modification. Below are research-focused FAQs based on peer-reviewed studies ( ).
How to validate SUMO-1 antibody specificity for Western blot?
-
Method: Perform parallel immunoblotting with recombinant SUMO-1/2/3/4 proteins and cell lysates (e.g., HEK293T ± SUMO overexpression).
-
Key controls:
-
Example data:
What factors influence SUMO-1 antibody performance in immunofluorescence (IF)?
-
Critical variables:
How to resolve contradictory SUMOylation data from different antibodies?
-
Scenario: Antibody A detects stress-induced SUMO-1 conjugates, while Antibody B shows no change.
-
Troubleshooting workflow:
How to design experiments detecting SUMO-1 in scFv-based assays?
-
Challenge: Single-chain variable fragments (scFvs) lack Fc regions, limiting detection by standard antibodies.
-
Solutions:
What methodologies identify SUMO-1-specific biomarkers in autoimmune diseases?
-
Approach:
-
Data interpretation:
